Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00310180
Registration number
NCT00310180
Ethics application status
Date submitted
29/03/2006
Date registered
3/04/2006
Date last updated
7/06/2024
Titles & IDs
Public title
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Query!
Scientific title
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment:The TAILORx Trial
Query!
Secondary ID [1]
0
0
NCI-2009-00707
Query!
Secondary ID [2]
0
0
NCI-2009-00707
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
TAILORx
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Adenocarcinoma
0
0
Query!
Hormone Receptor Positive
0
0
Query!
Stage IA Breast Cancer AJCC v7
0
0
Query!
Stage IB Breast Cancer AJCC v7
0
0
Query!
Stage IIA Breast Cancer AJCC v6 and v7
0
0
Query!
Stage IIB Breast Cancer AJCC v6 and v7
0
0
Query!
Stage IIIB Breast Cancer AJCC v7
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Anastrozole
Treatment: Drugs - Exemestane
Other interventions - Laboratory Biomarker Analysis
Treatment: Drugs - Letrozole
Other interventions - Quality-of-Life Assessment
Treatment: Other - Radiation Therapy
Treatment: Drugs - Tamoxifen Citrate
Experimental: Group 1 (Oncotype DX recurrence score =< 10) - Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.
Experimental: Group 2, Arm I (experimental) - Patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
Active Comparator: Group 2, Arm II (standard) - Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.
Experimental: Group 3 (Oncotype DX recurrence score >= 26) - Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in group two who are assigned to receive both types of treatment.
Treatment: Drugs: Anastrozole
Given PO
Treatment: Drugs: Exemestane
Given PO
Other interventions: Laboratory Biomarker Analysis
Correlative studies
Treatment: Drugs: Letrozole
Given PO
Other interventions: Quality-of-Life Assessment
Ancillary studies
Treatment: Other: Radiation Therapy
Undergo radiation therapy or partial breast irradiation
Treatment: Drugs: Tamoxifen Citrate
Given PO
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Intervention code [3]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
5-year Disease-free Survival
Query!
Assessment method [1]
0
0
Disease-free survival (DFS) is defined to be time from randomization to first event, where the first event is any of ipsilateral breast tumor recurrence, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary non-breast invasive cancer (excluding non-melanoma skin cancers), or death without evidence of recurrence. The distribution of DFS (eg, 5-year DFS rate) is estimated using Kaplan-Meier method, and compared between the two randomized arms (arm B vs. arm C) using stratified log rank test and stratified Cox proportional hazard model.
Query!
Timepoint [1]
0
0
Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years
Query!
Secondary outcome [1]
0
0
5-year Distant Recurrence-free Interval
Query!
Assessment method [1]
0
0
Distant recurrence-free interval (DRFI) is defined as time from date of randomization or registration to the date of distant recurrence of breast cancer, or of death with distant recurrence, if death is the first manifestation of distant recurrence. The distribution of DRFI (eg, 5-year DRFI rate) is estimated using Kaplan-Meier method.
Query!
Timepoint [1]
0
0
Assessed every 6 months within 5 years from registration and then annually up to 20 years, DRFI rate estimated at 5 years
Query!
Secondary outcome [2]
0
0
5-year Recurrence-free Interval
Query!
Assessment method [2]
0
0
Recurrence-free interval (RFS) is defined as time from date of randomization or registration to the date of first recurrence of breast cancer (ipsilateral breast tumor recurrence, local/regional recurrence, distant recurrence) or to the date of death with recurrence, if death is the first manifestation of recurrence. The distribution of RFS (eg, 5-year RFS rate) is estimated using Kaplan-Meier method.
Query!
Timepoint [2]
0
0
Assessed every 6 months within 5 years from registration and then annually up to 20 years, RFS rate estimated at 5 years
Query!
Secondary outcome [3]
0
0
5-year Overall Survival
Query!
Assessment method [3]
0
0
Overall survival (OS) is defined as time from date of randomization or registration to date of death from any cause. The distribution of OS (eg, 5-year OS rate) is estimated using Kaplan-Meier method.
Query!
Timepoint [3]
0
0
Assessed every 6 months within 5 years from registration and then annually up to 20 years, OS rate estimated at 5 years
Query!
Secondary outcome [4]
0
0
5-year Disease-free Survival by Age and Recurrence Score Groups
Query!
Assessment method [4]
0
0
Disease-free survival (DFS) is defined to be time from randomization to first event, where the first event is any of ipsilateral breast tumor recurrence, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary non-breast invasive cancer (excluding non-melanoma skin cancers), or death without evidence of recurrence. DFS is evaluated by recurrence score (0-10 vs. 11-15 vs. 16-20 vs. 21-25 vs. >25) and age groups (<=50 vs. 51-65 vs. 65-75). The distribution of DFS (eg, 5-year DFS rate) is estimated using Kaplan-Meier method.
Query!
Timepoint [4]
0
0
Assessed every 6 months within 5 years from registration and then annually up to 20 years, DFS rate estimated at 5 years
Query!
Secondary outcome [5]
0
0
To Compare the Outcomes Projected at 10 Years by Adjuvant! With Those Made by the Genomic Health Oncotype DX Test
Query!
Assessment method [5]
0
0
Adjuvant! is not currently available; additional work combining classical information with genomic tests will be reported separately.
Query!
Timepoint [5]
0
0
Assessed at 10 years after study entry
Query!
Secondary outcome [6]
0
0
5-year Disease-free Survival by Individual RS Gene Groups
Query!
Assessment method [6]
0
0
Disease-free survival (DFS) is defined to be time from randomization to first event, where the first event is any of ipsilateral breast tumor recurrence, local recurrence, regional recurrence, distant recurrence, contralateral second primary invasive cancer, second primary non-breast invasive cancer (excluding non-melanoma skin cancers), or death without evidence of recurrence. The distribution of DFS (eg, 5-year DFS rate) is estimated using Kaplan-Meier method. 5-year DFS by individual RS gene groups (Proliferation Gene Group, HER2 Gene Group, ER Gene Group, Invasion Gene Group, and Other Genes) will be estimated in each arm.
Query!
Timepoint [6]
0
0
Assessed every 6 months within 5 years from registration and then annually up to 20 years
Query!
Eligibility
Key inclusion criteria
- Patients with operable histologically confirmed adenocarcinoma of the female breast
who have completed primary surgical treatment and meet the following criteria:
- ER and/or progesterone receptor (PR)-positive: Estrogen and/or progesterone
receptor positive disease (as defined by local pathology laboratory)
- Negative axillary nodes: As assessed by a sentinel lymph node biopsy, an axillary
dissection, or both, and as defined by the Sixth Edition of the American Joint
Committee on Cancer (AJCC) staging criteria
- Tumor size 1.1-5.0 cm (or 5 mm-1.0 cm plus unfavorable histological features):
- Unfavorable features defined as intermediate or poor nuclear and/or
histologic grade, or lymphovascular invasion
- NOTE: Definition of tumor size: The tumor size used for determination of
eligibility is the pathologic tumor size, which is usually determined by the
size of the tumor as measured by inspection of the gross specimen; if the
tumor size is measured microscopically and the tumor includes ductal
carcinoma in-situ, the measurement should include only the invasive
component of the tumor
- The tumor must be human epidermal growth factor receptor 2 (Her2)/neu negative by
either fluorescent in-situ hybridization (FISH) or immunohistochemistry (e.g. 0
or 1+ by DAKO Herceptest)
- The patient and physician must be agreeable to initiate standard chemotherapy and
hormonal therapy as adjuvant therapy
- A tissue specimen from the primary breast cancer has been located and is ready to be
shipped to the appropriate laboratory after consent is obtained and within 3 days
following pre-registration; NOTE: For determination of the Oncotype Recurrence Score,
tissue must be shipped to Genomic Health; if the Oncotype DX Recurrence Score was
previously performed by Genomic Health (prior to pre-registration), tissue must be
submitted to the Eastern Cooperative Oncology Group (ECOG)-American College of
Radiology Imaging Network (ACRIN) Central Biorepository and Pathology Facility upon
randomization
- Leukocyte count >= 3500/mm^3
- Platelets >= 100,000/mm^3
- Serum creatinine =< 1.5 mg/dL
- Serum aspartate transaminase (AST) that is =< 3-fold the upper institutional limits of
normal
- Patients must be disease-free of prior invasive malignancies for >= 5 years with the
exception of curatively-treated basal cell or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix; patients with a previous ipsilateral or contralateral
invasive breast cancer, or with bilateral synchronous cancers, are not eligible;
patients with previous ipsilateral or contralateral ductal in situ carcinoma (DCIS)
are not eligible
- Prior treatment
- Mandatory prior surgery criteria:
- Patient must pre-register within 84 days from the final surgical procedure
required to adequately treat the primary tumor (please note that if margins
are not clear and a resection has to be conducted after pre-registration but
before randomization, the patient will be deemed to be within the 84 day
window allowed by protocol and therefore eligible)
- All tumors should be removed by either a mastectomy or local excision plus
an acceptable axillary procedure (i.e., sentinel lymph node biopsy, axillary
dissection, or both); there must be adequate (at least 1 mm if margin width
specified) tumor-free margins of resection (for invasive and ductal
carcinoma in-situ) in order for the patients to be eligible; patients with
lobular carcinoma in-situ involving the resection margins are eligible
- Criteria re: other prior treatments:
- No prior chemotherapy for this malignancy
- No prior radiation therapy for this malignancy; this includes no prior
MammoSite Brachytherapy radiation therapy (RT)
- Hormonal therapy: Patients who develop breast cancer while receiving a
selective estrogen-receptor modulator (SERM; e.g., tamoxifen, toremifene,
raloxifene) or an aromatase inhibitor (e.g., anastrazole, letrozole,
exemestane) for breast cancer prevention or a SERM for other indications
(e.g., raloxifene for osteoporosis) are not eligible; however, patients may
have received up to 8 weeks of a SERM or aromatase inhibitor for this
malignancy and still be eligible for study entry
- Patients must have an anticipated life expectancy of at least 10 years
- Patients with the following medical conditions should not be enrolled on the study:
- Chronic obstructive pulmonary disease requiring treatment
- Chronic liver disease (e.g., cirrhosis, chronic active hepatitis)
- Previous history of a cerebrovascular accident
- History of congestive heart failure or other cardiac disease that would represent
a contraindication to the use of an anthracycline (e.g., doxorubicin or
epirubicin)
- Chronic psychiatric condition or other condition that would impair compliance
with the treatment regimen
- Women must not be pregnant or breast-feeding; all females of childbearing potential
must have a blood test or urine study within 2 weeks prior to pre-registration to rule
out pregnancy
- Women of childbearing potential must be strongly advised to utilize an accepted
and effective form of non-hormonal contraception (e.g. intrauterine device,
condoms, diaphragm, abstinence)
- Patients must not have previously had the Oncotype DX Assay performed, with the
exception of patients who have had the assay performed and have a recurrence score of
11-25
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/04/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2030
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
10273
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Border Medical Oncology - Albury
Query!
Recruitment hospital [2]
0
0
Coffs Harbour Health Campus-North Coast Cancer Institute - Coffs Harbour
Query!
Recruitment hospital [3]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [4]
0
0
Lismore Base Hospital - Lismore
Query!
Recruitment hospital [5]
0
0
Lingard Private Hospital - Merewether
Query!
Recruitment hospital [6]
0
0
Royal Newcastle Hospital - New Castle
Query!
Recruitment hospital [7]
0
0
Calvary Mater Newcastle Hospital - Waratah
Query!
Recruitment hospital [8]
0
0
Royal Brisbane and Women's Hospital - Herston
Query!
Recruitment hospital [9]
0
0
Nambour Hospital - Nambour
Query!
Recruitment hospital [10]
0
0
Royal Hobart Hospital - Saint Hobart
Query!
Recruitment hospital [11]
0
0
Breast Unit-Mercy Private - East Melbourne
Query!
Recruitment hospital [12]
0
0
Epworth Hospital - Richmond
Query!
Recruitment hospital [13]
0
0
Saint John of God Hospital - Bunbury - Bunbury
Query!
Recruitment hospital [14]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2640 - Albury
Query!
Recruitment postcode(s) [2]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [3]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [4]
0
0
2480 - Lismore
Query!
Recruitment postcode(s) [5]
0
0
2191 - Merewether
Query!
Recruitment postcode(s) [6]
0
0
2300 - New Castle
Query!
Recruitment postcode(s) [7]
0
0
2310 - Waratah
Query!
Recruitment postcode(s) [8]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [9]
0
0
4560 - Nambour
Query!
Recruitment postcode(s) [10]
0
0
7000 - Saint Hobart
Query!
Recruitment postcode(s) [11]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [12]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [13]
0
0
6230 - Bunbury
Query!
Recruitment postcode(s) [14]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Arkansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
California
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Colorado
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Connecticut
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Delaware
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
District of Columbia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Florida
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Georgia
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Hawaii
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Idaho
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Illinois
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Indiana
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Iowa
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Kansas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Kentucky
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Louisiana
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Maine
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Maryland
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Massachusetts
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Michigan
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Minnesota
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Mississippi
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Missouri
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Montana
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Nebraska
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Nevada
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
New Hampshire
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
New Jersey
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
New Mexico
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
New York
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
North Carolina
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
North Dakota
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Ohio
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Oklahoma
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Oregon
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Pennsylvania
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Rhode Island
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
South Carolina
Query!
Country [42]
0
0
United States of America
Query!
State/province [42]
0
0
South Dakota
Query!
Country [43]
0
0
United States of America
Query!
State/province [43]
0
0
Tennessee
Query!
Country [44]
0
0
United States of America
Query!
State/province [44]
0
0
Texas
Query!
Country [45]
0
0
United States of America
Query!
State/province [45]
0
0
Utah
Query!
Country [46]
0
0
United States of America
Query!
State/province [46]
0
0
Vermont
Query!
Country [47]
0
0
United States of America
Query!
State/province [47]
0
0
Virginia
Query!
Country [48]
0
0
United States of America
Query!
State/province [48]
0
0
Washington
Query!
Country [49]
0
0
United States of America
Query!
State/province [49]
0
0
West Virginia
Query!
Country [50]
0
0
United States of America
Query!
State/province [50]
0
0
Wisconsin
Query!
Country [51]
0
0
United States of America
Query!
State/province [51]
0
0
Wyoming
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Alberta
Query!
Country [53]
0
0
Canada
Query!
State/province [53]
0
0
British Columbia
Query!
Country [54]
0
0
Canada
Query!
State/province [54]
0
0
Manitoba
Query!
Country [55]
0
0
Canada
Query!
State/province [55]
0
0
New Brunswick
Query!
Country [56]
0
0
Canada
Query!
State/province [56]
0
0
Ontario
Query!
Country [57]
0
0
Canada
Query!
State/province [57]
0
0
Quebec
Query!
Country [58]
0
0
Canada
Query!
State/province [58]
0
0
Saskatchewan
Query!
Country [59]
0
0
Ireland
Query!
State/province [59]
0
0
Co Cork
Query!
Country [60]
0
0
Ireland
Query!
State/province [60]
0
0
Co Dublin
Query!
Country [61]
0
0
Ireland
Query!
State/province [61]
0
0
Co Galway
Query!
Country [62]
0
0
Ireland
Query!
State/province [62]
0
0
Co Limerick
Query!
Country [63]
0
0
Ireland
Query!
State/province [63]
0
0
Co Sligo
Query!
Country [64]
0
0
Ireland
Query!
State/province [64]
0
0
Co Waterford
Query!
Country [65]
0
0
Ireland
Query!
State/province [65]
0
0
Cork
Query!
Country [66]
0
0
Ireland
Query!
State/province [66]
0
0
Dublin
Query!
Country [67]
0
0
Ireland
Query!
State/province [67]
0
0
Letterkenny
Query!
Country [68]
0
0
New Zealand
Query!
State/province [68]
0
0
Auckland
Query!
Country [69]
0
0
New Zealand
Query!
State/province [69]
0
0
Hamilton
Query!
Country [70]
0
0
New Zealand
Query!
State/province [70]
0
0
Wellington
Query!
Country [71]
0
0
Peru
Query!
State/province [71]
0
0
Lima
Query!
Country [72]
0
0
Puerto Rico
Query!
State/province [72]
0
0
San Juan
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Northern Ireland
Query!
Funding & Sponsors
Primary sponsor type
Government body
Query!
Name
National Cancer Institute (NCI)
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
American College of Surgeons
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Cancer and Leukemia Group B
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
NSABP Foundation Inc
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
NCIC Clinical Trials Group
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
North Central Cancer Treatment Group
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Other
Query!
Name [6]
0
0
SWOG Cancer Research Network
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized phase III trial studies the best individual therapy for women who have
node-negative, estrogen-receptor positive breast cancer by using a special test (Oncotype
DX), and whether hormone therapy alone or hormone therapy together with combination
chemotherapy is better for women who have an Oncotype DX recurrence score of 11-25. Estrogen
can cause the growth of breast cancer cells. Hormone therapy may fight breast cancer by
blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the
body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving hormone therapy together with more than one chemotherapy drug (combination
chemotherapy) has been shown to reduce the chance of breast cancer recurrence, but the
benefit of adding chemotherapy to hormone therapy for women with node-negative,
estrogen-receptor positive breast cancer is small. New tests may provide information about
which patients are more likely to benefit from chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00310180
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Joseph A Sparano
Query!
Address
0
0
ECOG-ACRIN Cancer Research Group
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00310180
Download to PDF